BPG is committed to discovery and dissemination of knowledge
JOURNAL HOME
  • Homepage
  • Online Submission
Number of total visits
30595753
Number of visits today
688
Number of downloads
12993429
MEMBERSHIP
BPG JOURNALS
Cited by in F6Publishing
For: Okimoto T, Mizukami K, Ogawa R, Okamoto K, Shuto M, Fukuda K, Kodama M, Murakami K. Esomeprazole- or rabeprazole-based triple therapy eradicated Helicobacter pylori comparably regardless of clarithromycin susceptibility and CYP2C19 genotypes. J Clin Biochem Nutr 2016;59:149-53. [PMID: 27698544 DOI: 10.3164/jcbn.16-18] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Ozaki H, Harada S, Takeuchi T, Kawaguchi S, Takahashi Y, Kojima Y, Ota K, Hongo Y, Ashida K, Sakaguchi M, Tokioka S, Sakamoto H, Furuta T, Tominaga K, Higuchi K. Vonoprazan, a Novel Potassium-Competitive Acid Blocker, Should Be Used for the Helicobacter pylori Eradication Therapy as First Choice: A Large Sample Study of Vonoprazan in Real World Compared with Our Randomized Control Trial Using Second-Generation Proton Pump Inhibitors for Helicobacter pylori Eradication Therapy. Digestion 2018;97:212-8. [PMID: 29393194 DOI: 10.1159/000485097] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
2 Zou Y, Qian X, Liu X, Song Y, Song C, Wu S, An Y, Yuan R, Wang Y, Xie Y. The effect of antibiotic resistance on Helicobacter pylori eradication efficacy: A systematic review and meta-analysis. Helicobacter 2020;25:e12714. [PMID: 32533599 DOI: 10.1111/hel.12714] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
Write to the Help Desk
© 2004-2022 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345